Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients

Acta Haematologica

Volumn 118, Issue 1, 2007, Pages 7-9

  Pirrotta, Maria Teresa ^a,b   Bocchia, Monica ^a   Bucalossi, Alessandro ^a   Defina, Marzia ^a   Forconi, Francesco ^a   Gozzetti, Alessandro ^a   Lauria, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CHILL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LIVER TOXICITY; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PILOT STUDY; PRIMARY HEALTH CARE; PRIORITY JOURNAL;

AGE FACTORS; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE;

EID: 34347356568     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100992     Document Type: Article

References (9)

1. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Prugnola M, De Paoli L, Di Bona E, Invernizzi R, Marmont F, Petti MC, Rigolin G, Ronco F, Spadano A, Tosti ME, Visani G, Mele A, Mandelli F: Survival of elderly patients with acute myeloid leukemia. Haematologica 2004;89:296-302.
2. Godwin JE, Smith SE: Acute myeloid leukemia in the older patient. Clin Rev Oncol Hemat 2003;48S:S17-S26.
3. Sievers EL: Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol Dis 2003;31:7-10.
4. Nabhan C, Rundhaugen LM, Riley MB, Rademaker A, Boehlke L, Jatoi M, Tallman MS: Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res 2005;29:53-57.
5. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukaemia in first recurrence. Cancer 2005;104:1442-1452.
6. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderi S, Thomas D, Estey E, Giles FJ: Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003;51:87-90.
7. Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gitani S, Visani G, Baccarani M: First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukemia patients. Leuk Res 2004;28:987-990.
8. Amadori S, Suciu S, Willemze R, Mandelli F, Selleslag D, Stauder R, Ho A, Denzlinger C, Leone G, Fabris P, Muus P, Vignetti M, Hagemeijer A, Beeldens F, Anak O, De Witte T; EORTC leukaemia group; GIMEMA leukaemia group: Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukaemia: a phase II study (AML-15) of the EORTC and GIMEMA leukaemia groups. Haematologica 2004;89:950-956.
9. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rothainer A, Culligan D, Hunter A, Prentice AG, Milligan DW: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003;102:4277-4283.